RhCMV-specific antibody responses in CD4+ T lymphocyte depleted CMV-seropositive reinfected macaques.

(A) Kinetic data of anti-gB binding antibodies in graphs on individual animals showing log ED50 of anti-gB binding titer (green line) superimposed on CD4+ lymphocytes/μL (red line). (B) Comparison of CMV-seropositive reinfected dams (n = 5) and CMV-seropositive controls (n = 3) by their anti-gB binding titer and fibroblast neutralization against RhCMV 180.92 at baseline preceding CD4+ lymphocyte depletion. (C) Difference from baseline value in anti-gB IgG ED50 titers in the CMV-seropositive reinfection groups at each of the post-infection time-points compared with CMV-seropositive controls at equivalent post CD4-depletion time-points. (D) Difference from baseline value in neutralization titer in the CMV-seropositive reinfection groups at each of the post-infection time-points compared with CMV-seropositive controls at equivalent post CD4-depletion time-points. ED50 = Effective Dose 50.